Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 1,610,000 shares, a drop of 6.4% from the September 15th total of 1,720,000 shares. Based on an average trading volume of 397,400 shares, the days-to-cover ratio is presently 4.1 days.
Castle Biosciences Trading Up 0.9 %
Shares of NASDAQ CSTL traded up $0.29 during trading on Wednesday, reaching $33.77. The stock had a trading volume of 428,344 shares, compared to its average volume of 314,091. The business’s 50-day moving average price is $29.30 and its 200-day moving average price is $24.43. Castle Biosciences has a fifty-two week low of $12.23 and a fifty-two week high of $34.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. The company has a market cap of $932.29 million, a P/E ratio of -29.37 and a beta of 1.03.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.47. The business had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same quarter in the prior year, the company earned ($0.70) earnings per share. On average, equities research analysts predict that Castle Biosciences will post -0.58 EPS for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Stock Report on CSTL
Insider Activity
In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of Castle Biosciences stock in a transaction on Monday, October 14th. The shares were sold at an average price of $32.27, for a total transaction of $63,636.44. Following the sale, the insider now owns 91,664 shares of the company’s stock, valued at $2,957,997.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Derek J. Maetzold sold 986 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the sale, the insider now directly owns 94,622 shares in the company, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Derek J. Maetzold sold 1,972 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $32.27, for a total value of $63,636.44. Following the completion of the sale, the insider now directly owns 91,664 shares of the company’s stock, valued at $2,957,997.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 45,476 shares of company stock worth $1,181,637 over the last quarter. 7.20% of the stock is currently owned by corporate insiders.
Institutional Trading of Castle Biosciences
A number of large investors have recently modified their holdings of the stock. RiverPark Advisors LLC grew its stake in Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after purchasing an additional 2,242 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Castle Biosciences by 70.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock worth $117,000 after buying an additional 2,187 shares in the last quarter. Denali Advisors LLC purchased a new stake in shares of Castle Biosciences during the first quarter worth approximately $186,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Castle Biosciences by 10.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock valued at $215,000 after acquiring an additional 952 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Castle Biosciences in the second quarter worth approximately $218,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Articles
- Five stocks we like better than Castle Biosciences
- NYSE Stocks Give Investors a Variety of Quality Options
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is the Hang Seng index?
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is the Australian Securities Exchange (ASX)
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.